GlassScriptPhysician profile
Steven D Gillon
NPI 1285668376
$2,246.43
in general payments reported to CMS, 2019-2025
25 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $541 · 2020: $756 · 2021: $519 · 2022: $176 · 2023: $98.22 · 2024: $156.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $241 · Education: $14.09.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $240.53 |
| Education | $14.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $389.94 | 2019-2024 | Xifaxan |
| Abbvie INC. | $361.33 | 2019-2023 | |
| Allergan, INC. | $290.21 | 2019-2020 | |
| Novo Nordisk INC | $227.95 | 2019-2023 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $183.09 | 2019-2023 | Farxiga |
| Pfizer INC. | $131.01 | 2019-2021 | |
| Gilead Sciences, INC. | $117.85 | 2019-2023 | |
| Redhill Biopharma INC. | $98.07 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $75.10 | 2019-2020 | |
| Qol Medical, LLC | $52.46 | 2021 | |
| Janssen Biotech, INC. | $46.59 | 2019-2023 | Stelara |
| Medtronic, INC. | $38.80 | 2024 | Minimed 780g |
| Intercept Pharmaceuticals, INC. | $28.38 | 2020 | |
| Shionogi INC | $24.78 | 2019 | |
| Ironwood Pharmaceuticals, INC | $23.60 | 2020 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $22.14 | 2024 | Ibsrela |
| Exact Sciences Corporation | $20.72 | 2024 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $15.00 | 2021 | |
| Janssen Pharmaceuticals, INC | $14.96 | 2019 | |
| Dova Pharmaceuticals | $14.80 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.30 | 2019 | |
| Glaxosmithkline, LLC. | $14.28 | 2021 | |
| Celltrion USA INC. | $14.09 | 2024 | Zymfentra |
| Phathom Pharmaceuticals, INC. | $13.94 | 2024 | Voquezna |
| Celgene Corporation | $13.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Gillon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.